Veracyte, Inc. VCYT
Set alert
As of Nov 3, 10:27 AM ET
- YTD
- +20.62%
- 1 year
- +39.31%
- Open
- 49.95
- Prev close
- 49.00
- Mkt cap
- 4.06B
- Vol
- 68.45K
- Avg vol
- 1.30M
- EPS
- 1.40
- P/E
- 36.11
- Div yield
- 0.00%
More statistics
- Low
- 49.88
- High
- 51.07
- Forward P/E
- 25.22
- Beta
- 1.96
- Short ratio
- 6.64
- Inst. own
- 115.10%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 44.42
- 200-d avg
- 42.82
- 1y target
- 59.73
5D chart
Signals (115)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 9:30 AM | 57 minutes ago |
| SMA: Bullish | Nov 3, 9:30 AM | 57 minutes ago |
| MACD: Buy Signal | Nov 3, 9:30 AM | 57 minutes ago |
| MACD: Sell Signal | Nov 2, 4:00 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 3:55 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 3:55 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 3:40 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 3:40 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 3:25 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 3:10 PM | 19 hours ago |
| MACD: Buy Signal | Nov 2, 3:00 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 2:55 PM | 19 hours ago |
| MACD: Sell Signal | Nov 2, 2:35 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 2:25 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 2:20 PM | 20 hours ago |
| SMA: Bullish | Nov 2, 2:10 PM | 20 hours ago |
| MACD: Buy Signal | Nov 2, 2:10 PM | 20 hours ago |
| SMA: Bullish | Nov 2, 2:05 PM | 20 hours ago |
| MACD: Sell Signal | Nov 2, 1:40 PM | 20 hours ago |
Newest 20 of 115.
News
1 day ago globenewswire.com
Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026
Two oral presentations mark Afirma's strongest podium presence in recent years, alongside eight posters Two oral presentations mark Afirma's strongest podium presence in recent years, alongside eight…
4 days ago globenewswire.com
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will be participating in the following investor…
6 days ago zacks.com
Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
2 weeks ago benzinga.com
Veracyte Announces Receiving Of Coverage For Its Prosigna Breast Risk Of Recurrence Test For Its Technical Assessment Submission Through Palmetto GBA’s MolDX Program
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Prosigna® Breast Risk of Recurrence (ROR) test has received coverage for its Technical Assessment…
3 weeks ago benzinga.com
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
-
1 month ago benzinga.com
Veracyte To Present New Findings From Retrospective Ancillary Analysis Of Randomized Phase III NRG/RTOG 0815 Trial At 2026 ASTRO Annual Meeting
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be…
1 month ago benzinga.com
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
-
1 month ago benzinga.com
Veracyte Acquires Convergent Genomics In $150M Deal, With Up To $30M Milestone Payments
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its…
-
1 month ago benzinga.com
UBS Maintains Buy on Veracyte, Raises Price Target to $65
UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $52 to $65.
2 months ago benzinga.com
Top 3 Health Care Stocks That Could Blast Off This Month
The health care sector's oversold stocks present buying opportunities for undervalued companies. RSI compares stock strength on up and down days, with an RSI below 30 considered oversold.
-
3 months ago benzinga.com
Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $54
Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $66 to $54.
-
3 months ago benzinga.com
Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $55
Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $68 to $55.
-
3 months ago benzinga.com
Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $44
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $47 to $44.
-
3 months ago benzinga.com
Canaccord Genuity Maintains Hold on Veracyte, Lowers Price Target to $50
Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and lowers the price target from $60 to $50.
3 months ago benzinga.com
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.
-
3 months ago benzinga.com
Needham Maintains Buy on Veracyte, Raises Price Target to $69
Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $57 to $69.
-
3 months ago benzinga.com
Veracyte Raises FY2026 Sales Guidance from $582.000M-$592.000M to $590.000M-$596.000M vs $586.445M Est
Veracyte (NASDAQ:VCYT) raises FY2026 sales outlook from $582.000 million-$592.000 million to $590.000 million-$596.000 million vs $586.445 million estimate.
3 months ago benzinga.com
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and TNGX with positive ratings and price targets.
-
3 months ago benzinga.com
Piper Sandler Initiates Coverage On Veracyte with Overweight Rating, Announces Price Target of $66
Piper Sandler analyst David Westenberg initiates coverage on Veracyte (NASDAQ:VCYT) with a Overweight rating and announces Price Target of $66.
-
3 months ago benzinga.com
Canaccord Genuity Maintains Hold on Veracyte, Raises Price Target to $60
Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the price target from $42 to $60.
-
3 months ago benzinga.com
Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $47
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raises the price target from $37 to $47.
-
4 months ago benzinga.com
Guggenheim Maintains Buy on Veracyte, Raises Price Target to $65
Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $45 to $65.
4 months ago benzinga.com
Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock
On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,502 shares of Kodiak AI
-
5 months ago benzinga.com
Needham Maintains Buy on Veracyte, Raises Price Target to $57
Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $48 to $57.
-
5 months ago benzinga.com
Veracyte Commercially Rolls Out Prosigna Breast Risk Of Recurrence Test Across U.S.
On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the U.S. commercial launch…
-
5 months ago benzinga.com
Veracyte To Present Results From Independent OPTIMA Trial, Led By University College London, At ASCO Annual Meeting
Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node…
-
6 months ago benzinga.com
Canaccord Genuity Maintains Hold on Veracyte, Raises Price Target to $42
Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the price target from $40 to $42.
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
6 months ago benzinga.com
Davita, Bloomin' Brands, Compass And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised guidance. Other gaining stocks include EVC, BLMN, MNKD, FLEX, HUT, AVTX, COMP, VCYT, and SSRM.
6 months ago benzinga.com
Full Transcript: Veracyte Q1 2026 Earnings Call
Full Transcript: Veracyte Q1 2026 Earnings Call
-
6 months ago benzinga.com
Veracyte Raises FY2026 Sales Guidance from $570.000M-$582.000M to $582.000M-$592.000M vs $576.521M Est
Veracyte (NASDAQ:VCYT) raises FY2026 sales outlook from $570.000 million-$582.000 million to $582.000 million-$592.000 million vs $576.521 million estimate.
-
6 months ago benzinga.com
Veracyte Q1 Adj. EPS $0.52 Beats $0.15 Estimate, Sales $139.071M Beat $130.041M Estimate
Veracyte (NASDAQ:VCYT) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.15 by 246.67 percent. This is a 67.74 percent increase over earnings of $0.31 per…
-
6 months ago benzinga.com
Canaccord Genuity Maintains Hold on Veracyte, Lowers Price Target to $40
Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and lowers the price target from $43 to $40.
-
6 months ago benzinga.com
Jefferies Initiates Coverage On Veracyte with Buy Rating, Announces Price Target of $45
Jefferies analyst Tycho Peterson initiates coverage on Veracyte (NASDAQ:VCYT) with a Buy rating and announces Price Target of $45.
-
7 months ago benzinga.com
Guggenheim Maintains Buy on Veracyte, Lowers Price Target to $45
Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $50 to $45.
-
8 months ago benzinga.com
Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $37
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $48 to $37.
-
8 months ago benzinga.com
Needham Maintains Buy on Veracyte, Raises Price Target to $48
Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $44 to $48.
-
8 months ago benzinga.com
Veracyte Affirms FY2026 Sales Guidance of $570.000M-$582.000M
Veracyte (NASDAQ:VCYT) affirms FY2026 sales outlook from $570.000 million-$582.000 million to $570.000 million-$582.000 million.
-
8 months ago benzinga.com
Veracyte Q4 Adj. EPS $0.53 Beats $0.36 Estimate, Sales $140.636M Beat $136.944M Estimate
Veracyte (NASDAQ:VCYT) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.36 by 47.22 percent. This is a 47.22 percent increase over earnings of $0.36 per…
-
8 months ago benzinga.com
Earnings Scheduled For February 25, 2026
Earnings Scheduled For February 25, 2026
-
9 months ago benzinga.com
Reported Earlier, Veracyte Reports Preliminary FY2025 Revenue Of $515M–$517M Up ~16% YoY With Strong Testing Volume Growth, Q4 Revenue Of $138M–$140M And Introduces 2026 Revenue Outlook Of $570M–$582M
For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report:Total revenue of between $138 million and $140 million, an increase of between 16%…
-
10 months ago benzinga.com
Guggenheim Maintains Buy on Veracyte, Raises Price Target to $50
Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $45 to $50.
11 months ago benzinga.com
Meihua International Medical Technologies, Fly-E Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Meihua International Medical Technologies, Fly-E Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
-
11 months ago benzinga.com
Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $48
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raises the price target from $40 to $48.
-
11 months ago benzinga.com
Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $40
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raises the price target from $28 to $40.
-
12 months ago benzinga.com
Canaccord Genuity Maintains Hold on Veracyte, Raises Price Target to $43
Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the price target from $40 to $43.
12 months ago benzinga.com
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
-
12 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session